Drugs / Flu Seasonal /SARS-CoV-2 mRNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06680375 | Nov 2024 → Jun 2025 | COVID-19 | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flu Seasonal /SARS-CoV-2 mRNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06680375 ↗ |
| Known as | mRNA Flu/COVID-19 | “Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine” NCT06680375 ↗ |
| Modality | Messenger RNA (mRNA) | “A Flu mRNA vaccine composition in combination with Dose 1 of a COVID-19 component will be administered.” NCT06680375 ↗ |